DARVOCET-N 100

Compare DARVOCET-N 100  to:
Compare
Compare

Generic Name for DARVOCET-N 100

Propoxyphene napsylate 100mg, acetaminophen 650mg; tabs.

Legal Classification:

CIV

Pharmacological Class for DARVOCET-N 100

Opioid + analgesic.

Manufacturer of DARVOCET-N 100

Xanodyne Pharmacal, Inc.

Indications for DARVOCET-N 100

Mild to moderate pain.

Adult dose for DARVOCET-N 100

1 tab every 4 hrs as needed; max 6/day.

Children's dosing for DARVOCET-N 100

Not recommended.

Also:

Contraindications for DARVOCET-N 100

Suicidal or addiction-prone patients.

Precautions for DARVOCET-N 100

Renal or hepatic impairment. Elderly. Debilitated. Labor & delivery. Pregnancy. Nursing mothers.

Interactions for DARVOCET-N 100

Potentiation with alcohol, CNS depressants. May increase levels of antidepressants, anticonvulsants, coumarin anticoagulants, others. Coma, severe neurological effects seen with carbamazepine.

Adverse Reactions for DARVOCET-N 100

Dizziness, sedation, nausea, vomiting, constipation, rash; respiratory depression, hepatotoxicity (overdosage).

How is DARVOCET-N 100 supplied?

N-50, A500—100
N-100—100, 500

Related Disease:

Pain, general~narcotics

Related Resources

Exalgo approved for moderate to severe pain

March 02, 2010

The FDA has approved Exalgo (hydromorphone HCl extended-release tablets, from Covidien) for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

Phase 3 study of MoxDuo IR for pain management

February 10, 2010

QRxPharma Limited announced initiation of a second Phase 3 registration trial (Study 009) to evaluate its MoxDuo IR (morphine and oxycodone) product for the management of moderate to severe pain in patients who have undergone total knee replacement surgery.

FDA-approved morphine sulfate oral solution 100mg/5mL available

January 27, 2010

Roxane Laboratories announced that the New Drug Application (NDA) for high concentrate morphine sulfate oral solution 100mg/5mL (20mg/mL) has been approved by the FDA.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

NDA submitted for extended-release tapentadol tablets for chronic pain

December 02, 2009

Johnson & Johnson and its subsidiaries, PriCara and Ortho-McNeil-Janssen, announced that they have submitted a New Drug Application (NDA) to the FDA for tapentadol extended release (ER) tablets for the management of moderate to severe chronic pain in patients ≥18 years of age.